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Abstract
Increasing antibiotic resistance among multidrug resistant pathogens necessitates the search for newer antimicrobials.  
Streptomyces historically produce the largest number of antibacterials and herein we describe isolation of antagonists from 
extremophiles using unusual culture media. Antagonists or antimicrobials produced under extremophile environmental 
conditions demonstrated activity against MRSA from Kazakhstan and the United States.
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Introduction
Staphylococcus aureus colonization of the nose is common 
in the United States with an estimated 30% of the 
population carrying the organism asymptomatically [1]. 
However, S. aureus is an opportunistic pathogen accounting 
for as many as 478,000 hospitalizations as recently as 2005, 
more than half of which were due to methicillin-resistant 
S. aureus (MRSA) [2]. In fact, MRSA is the leading cause of 
multidrug resistant (MDR) hospital-associated infections 
in the United States [3]. MDR infections are associated with 
increased mortality, cost of care, and length of hospital stay 
[4,5,6,7]. Few antibiotic therapies are currently available 
to treat these multidrug-resistant pathogens and strains 
are increasingly insusceptible to new therapies.
Previously our laboratory has demonstrated that a 
compound produced by Streptomyces isolated from the 
soils of Kazakhstan possesses anti-Staphylococcal activity 
[8]. Historically, Streptomyces has been shown to be the 
largest antibiotic-producing genus [9] and consequently 
most clinically-used antibiotics are natural products 
or synthetic derivatives from the soil actinomycetes 
[10,11,12]. Mathematical modeling suggests that less 
than 10% of the antimicrobial compounds capable of 
being produced by Streptomyces sp. have been discovered 
[9,11]. Theories for the decline in soil actinomycetes-derived 
antibiotic discovery include decreased screening efforts 
and lack of focus on culture conditions, and these are the 
basis of the current study.
Because our earlier study suggested that antimicrobials 
may be produced by actinomycetes when grown under 
stress conditions, we collected 5,936 strains from 
Kazakhstan soil and marine environments exhibiting 
high salinity and/or alkalinity (unpublished: Institute of 
Microbiology and Virology Report). From this, a total of 
2,019 isolates which were morphologically consistent with 
actinomycetes were grown on variations of Bennett’s 
agar, which differed by salt and pH concentration 
to approximate the extremophile’s environmental 
conditions. The culture conditions used included three 
variants of Bennett’s agar; a neutral medium of pH of 7.2 
(medium 1), a saline medium with 5% NaCl added 
(medium 2), and an alkaline medium with 0.5% Na2CO3 
of pH 9.0 (medium 3). Potential antimicrobials were 
then isolated from the culture broths using extraction 
and chromatography methods as previously described 
[8]. A total of 424 of the extremophile strains produced 
antagonists, the majority of which exhibited inhibition 
against a Kazakhstan hospital-associated MRSA (HA-MRSA), 
when grown in extreme conditions (data not shown) 
using the standard disk diffusion assay [13]. We propose 
that actinomycetes may produce novel antimicrobials 
when cultivated under stress conditions and that these 
compounds have not previously been recognized due to 
the use of neutral culture conditions. The ability to produce 
antimicrobial compounds under stress conditions may 
provide the Streptomyces with an ecological advantage in 
extreme environments such as those found in Kazakhstan. 
We propose that anti-MDR antibiotics may be developed 
from these natural producers much like those currently 
in development from other unusual sources [10,11,13,14] 
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and that further screening of these compounds is warranted.
Geographical studies of the distribution of epidemic MRSA 
have demonstrated that the prominent strains in the United 
States differ from those found in the Kazakhstan region 
[15,16,17] suggesting that antibiotic efficacy is not equivalent 
worldwide. Therefore we selected fourteen of the purified 
anti-staphylococcal compounds produced by the Kazakhstan 
extremophiles for disk diffusion susceptibility testing using 
HA-MRSA in the United States. Table 1 lists the fourteen 
antimicrobial products tested, the stress conditions used 
to produce the antagonists, the environment from which 
the actinomycetes producer was isolated, and the observed 
zone of inhibition against the Kazakhstan HA-MRSA isolate. 
Sterile disks containing the Kazakhstan antimicrobials were 
prepared as previously described [8] and disk diffusion 
susceptibility assay against HA-MRSA was performed using 
the standard Kirby-Bauer protocol [18]. While the fourteen 
antagonists tested displayed varied degrees of inhibition 
against Kazakhstan HA-MRSA, less than half (5 of 14) inhibited 
US HA-MRSA (Table 1). These data are consistent with the 
known geographical differences in antibiotic resistance 
profiles namely in that MRSA strains from the United States 
are resistant to more antibiotics than those in the Kazakhstan 
region. These data suggest that the screening method used 
here in is a valuable tool in identifying potential antibiotics of 
worldwide utility and future work will include the continued 
susceptibility testing of the compounds against a wider 
variety of Staphylococcus isolates.
Studies suggest that the classical methodology of 
screening natural products, particularly those produced 
by bacterial sources, for antibacterial properties is far from 
reaching its potential [10] despite a decline in the use of these 
methods. Antibiotic production from natural products may 
see resurgence as few new synthetic compounds are available 
and genomic approaches have been largely disappointing. 
Our data suggest that antagonists produced by actinomycetes 
when cultivated under stress conditions inhibit MDR strains 
of Staphylococcus aureus. We therefore suggest that high 
throughput screening of additional Kazakhstan extremophile 
products incorporating inhibition assays against global MDR 
isolates is warranted. 
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Antagonist #
and Source (pH)
Zone of Inhibition  
(Kazakhstan HA-MRSA) 
(mm) United States HA-MRSA
Zone of Inhibitione (mm)Growth       Media
1a 2b 3c
2-2 mud (9.1) 0 18 NG 0
6-12 rhizosphere 
(8.6)
0 25 NG 0
18-7 sandy soil 
(10.0)
13 44 NG 0
19-25 soil (9.3) 0 35 0 11.5
33-1 mud (9.6) NGd 49 39 10.0
36-3 meadow  
soil (8.3)
10 24 23 0
41-8 saline soil 
(10.0)
11 29 15 7.0
48-29 sandy soil 
(10.0)
0 32 22 20.5
51-9 rhizosphere 
(9.5)
10 46 10 0
58-22 rhizosphere 
(8.9)
0 18 14 22.5
72-1 soil (9.6) 0 50 NG 0
96-1 soil (8.6) 11 26 19 0
Q4-39 soil (10.0) 0 16 15 0
Y-45 rhizosphere 
(9.8)
0 20 16 0
Table 1. Inhibition of Kazakhstan and US HA-MRSA by 
Actinomycetes Antagonists.
a Growth Medium 1 = Modified Bennett’s pH=7.2.
b Growth Medium 2 = Modified Bennett’s pH=7.2, 5% NaCl.
c Growth Medium 3 = Modified Bennett’s pH=9.0, 0.5% Na2CO3. 
d NG = No growth of the Actinomycetes producer.
e Zone of Inhibition for US HA-MRSA reported is an average of 
multiple Disk diffusion assays (DDA's).
Notes on Growth Medium:
Modified Bennett’s Growth Media 1a, 2b and 3c comprised of  
glucose (0.2%), peptone (0.2%), yeast extract (0.1%), and agar 
(2%), were used to grow actinomycete strains and incubated at 
28°C, and growth was checked after 1-2 weeks incubation.  
Purified isolates were investigated in antibacterial tests against 
Kazakhstan HA-MRSA using the standard disc diffusion assay; 
strains with positive anti-MRSA activities were chosen for 
preparation of Kazakhstan (KZ) extracts.
Notes on Antagonistic KZ extract antibacterial testing against 
Kazakhstan and United States HA-MRSA:
Fourteen KZ extracts (first column of Table 1 labeled as 
“Antagonistic #”) containing components with antibacterial 
activities shipped from Kazakhstan were tested in antagonistic  
tests against United States HA-MRSA grown on Mueller-
Hinton agar plates, using standard Kirby-Bauer disc diffusion 
assay. Dilution of KZ extracts and antibacterial testing were 
performed using similar conditions for HA-MRSA isolates from 
Kazakhstan and United States, using our previously reported 
methods [8]. Sterile disks containing 10 μg/mL of crude powder 
of KZ extracts were placed on fresh plates of the Mueller-Hinton 
agar seeded with bacterial suspensions at a cell density of 5×105 
CFU/ml of overnight cultures of the test.
HA-MRSA strains. The diameters of the zones of inhibition 
of growth (mm) around the disks measured after incubation 
periods of 18 h at 370C presented are average values from 
triplicate experiments.
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